Ozempic, Mounjaro, and other glucagon-like peptide-1 medications, otherwise known as GLP-1s, are changing how Americans shop for groceries. In early January, Food & Wine published a story about ...

However, a new class of medications, GLP-1 agonists, originally designed for diabetes and obesity management, shows promise as a revolutionary tool in addiction treatment. GLP-1, or glucagon-like ...

In a meta-analysis of nine randomized controlled trials, adults had an average lean mass loss of 2.5 kg with GLP-1 therapy. More research is needed to examine the implications of lean mass loss ...

We recently compiled a list of the Top 10 AI Stocks Dominating Wall Street. In this article, we are going to take a look at ...

A gut microbe has been identified that mimics the effects of Ozempic to mitigate diabetes and obesity. Here's how to take ...

Dr. Reddy's Lab is poised to witness crosswinds from a drop in revenue from the patent expiration of Revlimid and increased ...

We recently compiled a list of the 8 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where ...

The nature of the beast is yes, these drugs come off patent; the demand is there and someone could produce it more cheaply’, ...

Jim Cramer, host of Mad Money, recently discussed some of the significant challenges the alcohol industry is facing. He ...

With one in eight Americans having taken a GLP-1 already — including 43% of those with diabetes and a quarter of people with heart disease — it’s time to shift our thinking on GLP-1s to ...

Brown-Forman (NYSE:BF-B) is involved in the production, marketing, and sale of a wide range of alcoholic beverages, including ...